US 20210284988A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0284988 A1**

Spiegel et al. (43) **Pub. Date: Sep. 16, 2021**

(54) **REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT**

(71) Applicant: **YALE UNIVERSITY**, NEW HAVEN, CT (US)

(72) Inventors: **David A. Spiegel**, New Haven, CT (US); **Charles E. Jakobsche**, Worcester, MA (US)

(21) Appl. No.: **17/182,437**

(22) Filed: **Feb. 23, 2021**

Related U.S. Application Data

(60) Division of application No. 16/149,299, filed on Oct. 2, 2018, now Pat. No. 10,961,527, which is a continuation of application No. 14/356,820, filed on May 7, 2014, now abandoned, filed as application No. PCT/US2012/063844 on Nov. 7, 2012.

(60) Provisional application No. 61/558,811, filed on Nov. 11, 2011.

Publication Classification

(51) **Int. Cl.**

C12N 9/96	(2006.01)
A61K 45/06	(2006.01)
C07D 493/10	(2006.01)
A61K 31/165	(2006.01)
A61K 31/365	(2006.01)
C07C 279/12	(2006.01)
A61K 47/60	(2006.01)
A61K 47/54	(2006.01)
A61K 31/352	(2006.01)
A61K 38/05	(2006.01)
A61K 38/48	(2006.01)
C07D 491/107	(2006.01)
C07K 5/062	(2006.01)

(52) **U.S. Cl.**

CPC ***C12N 9/96*** (2013.01); ***A61K 45/06*** (2013.01); ***C07D 493/10*** (2013.01); ***A61K 31/165*** (2013.01); ***A61K 31/365*** (2013.01); ***C07C 279/12*** (2013.01); ***C07K 5/06026*** (2013.01); ***A61K 47/54*** (2017.08); ***A61K 31/352*** (2013.01); ***A61K 38/05*** (2013.01); ***A61K 38/482*** (2013.01); ***C07D 491/107*** (2013.01); ***A61K 47/60*** (2017.08)

(57) **ABSTRACT**

The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit ovrexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.